Did Sharon Osbourne confirm she used Ozempic?

Yes. Osbourne confirmed semaglutide (Ozempic) use in multiple televised interviews in 2023, including appearances with Piers Morgan and on Dr. Phil. This is not speculation.

How much weight did Sharon Osbourne say she lost on Ozempic?

Osbourne publicly stated she lost approximately 30 pounds. She described this amount as excessive and used the word "scrawny" to characterize her resulting appearance.

Why is GLP-1 weight loss riskier for older adults?

Adults over 65 lose 1% to 2% of skeletal muscle mass annually through sarcopenia. GLP-1 agonists cause 30% to 40% of total weight loss to come from lean mass. The combination can push older patients past functional thresholds, increasing fall risk and reducing independence.

What happens when you stop Ozempic after significant weight loss?

Clinical data from the STEP 1 extension trial shows that patients regain roughly two-thirds of lost weight within a year of stopping semaglutide. The regained weight is disproportionately fat rather than muscle, potentially leaving body composition worse than baseline.

Is Ozempic FDA-approved for weight loss?

Ozempic (semaglutide 0.5 mg and 1 mg) is FDA-approved for type 2 diabetes. Wegovy (semaglutide 2.4 mg) is the formulation approved for chronic weight management. Ozempic is frequently prescribed off-label for weight loss, which is how many public figures have described using it.

Sharon Osbourne Transformation Timeline: Public Photos, Public Statements, and the Medical Context

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Celebrity: Sharon Osbourne (born 1952)
Drug confirmed: Ozempic (semaglutide 0.25 mg to 1 mg subcutaneous injection, approved for type 2 diabetes; widely prescribed off-label for weight management)
Status: Confirmed by Osbourne herself in multiple televised interviews (2023)
Outcome described: Excessive, unwanted weight loss; discontinuation
Clinical theme: GLP-1 receptor agonist use in adults over 65 and the risk of disproportionate lean mass loss

The Public Record: What Sharon Osbourne Actually Said

Sharon Osbourne's Ozempic disclosure did not follow the usual celebrity wellness-reveal script. There was no "new chapter" framing, no brand partnership. She confirmed semaglutide use and, in the same breath, said it had gone wrong.

In a May 2023 appearance on the Talk TV program hosted by Piers Morgan, Osbourne confirmed she had been using Ozempic. She stated she had lost approximately 30 pounds. She described looking in the mirror and feeling the loss was excessive, using the word "scrawny" to characterize her appearance.

In a September 2023 interview with the Daily Mail, she expanded on this account. She called the weight loss "too much" and described the experience as frightening. She confirmed she had stopped taking the drug. She told interviewers she had difficulty regaining weight after discontinuation.

By late 2023, Osbourne appeared on Dr. Phil and other programs reiterating that she had lost more weight than she wanted and struggled to stabilize. She did not disclose her prescribing physician, her dose, or how long she had been on the medication. Those details remain private and the HealthRX Medical Team will not speculate on them.

What Osbourne gave the public record is this: a woman in her early 70s used a GLP-1 receptor agonist, lost weight rapidly, found the result alarming, and stopped.

Clinical Context: How Semaglutide Works and Why Age Changes the Equation

Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, which is released from the gut after eating. The drug slows gastric emptying, reduces appetite through hypothalamic signaling, and improves insulin secretion in a glucose-dependent manner. The FDA approved the 2.4 mg weekly dose (branded as Wegovy) specifically for chronic weight management in 2021. Ozempic, the formulation Osbourne named, is approved for type 2 diabetes at lower doses (0.5 mg and 1 mg) but has been widely prescribed off-label for weight loss.

In the key STEP 1 trial, adults on semaglutide 2.4 mg lost a mean of 14.9% of body weight over 68 weeks. But that headline number conceals an important detail: roughly 30% to 40% of weight lost on GLP-1 agonists comes from lean mass, not fat. In younger adults with substantial fat reserves, that ratio is manageable. In older adults, it is a different clinical picture entirely.

Adults over 65 already lose approximately 1% to 2% of skeletal muscle mass per year through age-related sarcopenia. Layering pharmacological appetite suppression on top of this baseline loss creates a compounding problem. A 2021 analysis in The Lancet on semaglutide's body composition effects confirmed that lean mass loss was proportionally significant, particularly in participants with lower baseline BMI.

The HealthRX Medical Team's read on this: for patients in their 70s, the margin between therapeutic weight reduction and functional impairment is narrow. Osbourne's public experience, losing more than intended and finding it difficult to reverse, maps directly onto what geriatric obesity specialists warn about.

The "Too Much" Problem: Why Stopping Doesn't Immediately Fix It

Osbourne described struggling to regain weight after discontinuing Ozempic. This is consistent with what clinicians observe. GLP-1 receptor agonists suppress appetite through central nervous system pathways. When the drug clears the system (semaglutide has a half-life of approximately one week), appetite typically returns. But in older adults who have already lost significant lean mass, the rebound is not symmetrical.

Research published in JAMA on the STEP 1 extension trial showed that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. The critical finding: the weight regained was disproportionately fat, not muscle. This means the body composition after a use-and-stop cycle can be worse than before treatment began. Clinicians refer to this pattern as "weight cycling with adverse recomposition."

For a woman in her early 70s, regaining fat without proportional muscle recovery increases fall risk, reduces functional independence, and worsens metabolic health markers even if the scale returns to a previous number.

What the HealthRX Medical Team Wants You to Understand

Sharon Osbourne's public account is valuable precisely because it breaks from the dominant "GLP-1 success story" narrative. The HealthRX Medical Team sees three clinical takeaways in her documented experience:

1. Age-appropriate dosing protocols matter. The American Geriatrics Society has noted that older adults may require lower target doses or slower titration schedules. Standard protocols designed around trial populations with mean ages in the mid-40s may produce excessive effects in patients over 65. Without knowing Osbourne's dose or titration schedule (she has not disclosed these), the HealthRX Medical Team cannot comment on her specific regimen. The general principle stands: older patients require individualized approaches.

2. Body composition monitoring should accompany GLP-1 prescriptions in older adults. Scale weight alone is insufficient. Dual-energy X-ray absorptiometry (DEXA) or bioimpedance analysis at baseline and regular intervals can flag when lean mass loss exceeds acceptable thresholds. The HealthRX Medical Team recommends this for any patient over 60 on a GLP-1 agonist.

3. Concurrent resistance training is not optional in this population. A 2024 study in The New England Journal of Medicine on tirzepatide confirmed that structured exercise during GLP-1 therapy can shift the lean-to-fat loss ratio meaningfully. For older adults, resistance training two to three times per week is a clinical safeguard, not a lifestyle suggestion.

The Broader Pattern: Osbourne Is Not Alone

Osbourne's disclosure arrived during a period when several public figures over 60 were openly discussing GLP-1 use. While this page focuses on Osbourne's documented experience, the HealthRX Medical Team notes that her account fits a pattern visible in clinical practice: older patients who respond to semaglutide with faster or more pronounced weight loss than expected, sometimes dropping below their own target weight before they or their physicians adjust course.

The FDA's adverse event reporting system includes reports of unintended excessive weight loss with semaglutide, though the agency has not issued specific age-stratified warnings beyond the existing labeling. The HealthRX Medical Team considers this a gap. Age-specific guidance from the FDA or the Endocrine Society on GLP-1 use in patients over 65 would help clinicians calibrate risk.

What Osbourne's Story Does Not Tell Us

The public record has limits. Osbourne has not disclosed:

Her starting or ending weight
Whether she was prescribed Ozempic for diabetes, weight management, or another indication
Her dose or duration of treatment
Whether she used any concurrent medications
Whether she engaged in structured exercise during treatment

The HealthRX Medical Team does not speculate on these details. The clinical commentary above is based on general pharmacology and published trial data, not assumptions about Osbourne's private medical care.

Frequently asked questions

›